PUMA BIOTECHNOLOGY, INC. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 52/100
What the filing says
PUMA Biotechnology executed a Ninth Amendment to its Note Purchase Agreement with Athyrium Opportunities IV Co-Invest 1 LP (lender and administrative agent) on April 16, 2026, extending the "Qualified Equity Issuance" deadline from April 30, 2026 to July 23, 2026. This amendment affects Section 7.23 and related schedules of the underlying debt facility originally dated July 23, 2021. No dollar amounts, share counts, or additional financial terms were disclosed in the filing.
Why this rating
Deadline extension signals equity-raising difficulty; repeated amendments (9th amendment) suggest persistent covenant pressure. Moderate concern for $145M company relying on lender forbearance.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.